At a glance
ClinicalIndex Comparison RecordN/ACompleted· 22 enrolled
Drug / intervention
Probioticdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exploratory, Randomized, Double-blind, Placebo-Controlled Study on the Effects of Bifidobacterium Infantis in Active Celiac Disease
In Brief
A clinical study evaluating Probiotic for Celiac Disease. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This exploratory study has been designed to determine the effect of the probiotic Bifidobacterium infantis vs. placebo orally administered over a period of 3 weeks on clinical features, Quality of Life parameters (QoL), intestinal permeability and inflammatory markers of patients having positive serological evidences of Celiac Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCeliac Disease
CountriesArgentina
CollaboratorsThe National Institute of Probiotics
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedDec 2010
Primary CompletionSep 2011
Study CompletionDec 2011
TodayJul 2026
First PostedDec 10, 2010
Enrollment StartDec 1, 2010
Primary CompletionSep 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.6 years ago
Interventions
Probioticdietary
Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.